Antigenics Provides Update on Filing for Approval of Oncophage(R) in Russia for the Treatment of Intermediate-Risk Kidney Cancer.
Business Wire › August 02, 2007
Linked as:
Extract
Antigenics Provides Update on Filing for Approval of Oncophage(R) in Russia for the Treatment of Intermediate-Risk Kidney Cancer.
Application Based on Investigator-Reported Results of Phase 3 Study Showing That Oncophage Significantly Prolongs Recurrence-Free Survival by 45 Percent in Patients With Intermediate-Risk Kidney Cancer
NEW YORK -- Antigenics Inc. (NASDAQ: AGEN) today announced that it has completed the submission of an application for marketing authorization with the Russian Ministry of Public Health for the ...See the full content of this document
Sponsored links
